It's Wednesday, November 26. Today, we discuss groundbreaking advancements in gene therapy for spinal muscular atrophy, explore the implications of new research on in vivo gene editing, and highlight the latest FDA approval for Novartis' Itvisma.
Kilder
- Nature: Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence - Nature
- Nature: Chemical strategies for brain delivery of genomic therapy - Nature
- Nature: Intravaginal delivery of mRNA-encoded antibodies with enhanced breadth and potency for SHIV/HIV protection - Nature
- Biospace: Novartis Expands Spinal Muscular Atrophy Gene Therapy Market With FDA’s Itvisma Greenlight - BioSpace
- Bioworld: Novartis’ Itvisma wins US FDA approval for SMA patients ages 2+ - BioWorld MedTech
- Bioworld: Gene therapies aim for the big goal of edits in vivo - BioWorld MedTech
Oppsummeringen og talen er laget med KI. Kildelenkene viser opphavet og er ikke en anbefaling av TellMe fra mediene.